Mutational analysis of Polycomb genes in solid tumours identifies PHC3 amplification as a possible cancer-driving genetic alteration

British Journal of Cancer

Volumn 109, Issue 6, 2013, Pages 1699-1702

  Crea, F ^a   Sun, L ^b   Pikor, L ^a   Frumento, P ^c   Lam, W L ^a   Helgason, C D ^a,d  

^a BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

^b FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

^c KAROLINSKA INSTITUTE   (Sweden)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; PHC3 PROTEIN; POLYCOMB GROUP PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; GENE AMPLIFICATION; GENE OVEREXPRESSION; HUMAN; LUNG CARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MISSENSE MUTATION; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; SOLID TUMOR; UTERUS CARCINOMA;

DNA MUTATIONAL ANALYSIS; ENDOMETRIAL NEOPLASMS; EPIGENOMICS; FEMALE; GENE AMPLIFICATION; HUMANS; LUNG NEOPLASMS; MALE; MUTATION; NEOPLASMS; POLYCOMB REPRESSIVE COMPLEX 1; PROGNOSIS; RNA, MESSENGER;

EID: 84884587354     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.454     Document Type: Article

References (18)

1. Baylin SB, Jones PA (2011) A decade of exploring the cancer epigenome - biological and translational implications. Nat Rev Cancer 11(10): 726-734.
2. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, Antipin Y, Reva B, Goldberg AP, Sander C, Schultz N (2012) The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data Cancer Discov 2(5): 401-404.
3. Chase A, Cross NC (2011) Aberrations of EZH2 in cancer. Clin Cancer Res 17(9): 2613-2618.
4. Christophersen NS, Helin K (2010) Epigenetic control of embryonic stem cell fate. J Exp Med 207(11): 2287-2295.
5. Crea F, Paolicchi E, Marquez VE, Danesi R (2012) Polycomb genes and cancer: Time for clinical application? Crit Rev Oncol/Hematol 83(2): 184-193.
6. Deshpande AM, Akunowicz JD, Reveles XT, Patel BB, Saria EA, Gorlick RG, Naylor SL, Leach RJ, Hansen MF (2007) PHC3, a component of the hPRC-H complex, associates with E2F6 during G0 and is lost in osteosarcoma tumors. Oncogene 26(12): 1714-1722.
7. Hussain M, Rao M, Humphries AE, Hong JA, Liu F, Yang M, Caragacianu D, Schrump DS (2009) Tobacco smoke induces polycomb-mediated repression of Dickkopf-1 in lung cancer cells. Cancer Res 69(8): 3570-3578.
8. Lavigne M, Francis NJ, King IF, Kingston RE (2004) Propagation of silencing; recruitment and repression of naive chromatin in trans by polycomb repressed chromatin. Mol Cell 13(3): 415-425.
9. Linxweiler M, Linxweiler J, Barth M, Benedix J, Jung V, Kim YJ, Bohle RM, Zimmermann R, Greiner M (2012) Sec62 bridges the gap from 3q amplification to molecular cell biology in non-small cell lung cancer. Am J Pathol 180(2): 473-483.
10. McCabe MT, Ott HM, Ganji G, Korenchuk S, Thompson C, Van Aller GS, Liu Y, Graves AP, Iii AD, Diaz E, Lafrance LV, Mellinger M, Duquenne C, Tian X, Kruger RG, McHugh CF, Brandt M, Miller WH, Dhanak D, Verma SK, Tummino PJ, Creasy CL (2012) EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 492(7427): 108-112.
11. Melnick A (2012) Epigenetic therapy leaps ahead with specific targeting of EZH2. Cancer Cell 22(5): 569-570.
12. Pelosi G, Del Curto B, Trubia M, Nicholson AG, Manzotti M, Veronesi G, Spaggiari L, Maisonneuve P, Pasini F, Terzi A, Iannucci A, Viale G (2007) 3q26 Amplification and polysomy of chromosome 3 in squamous cell lesions of the lung: A fluorescence in situ hybridization study. Clin Cancer Res 13(7): 1995-2004.
13. Piekarz RL, Bates SE (2009) Epigenetic modifiers: Basic understanding and clinical development. Clin Cancer Res 15(12): 3918-3926.
14. Regala RP, Davis RK, Kunz A, Khoor A, Leitges M, Fields AP (2009) Atypical protein kinase C{iota} is required for bronchioalveolar stem cell expansion and lung tumorigenesis. Cancer Res 69(19): 7603-7611.
15. Rhodes DR, Kalyana-Sundaram S, Mahavisno V, Varambally R, Yu J, Briggs BB, Barrette TR, Anstet MJ, Kincead-Beal C, Kulkarni P, Varambally S, Ghosh D, Chinnaiyan AM (2007) Oncomine 3.0: Genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia 9(2): 166-180.
16. Starczynowski DT, Lockwood WW, Delehouzee S, Chari R, Wegrzyn J, Fuller M, Tsao MS, Lam S, Gazdar AF, Lam WL, Karsan A (2011) TRAF6 is an amplified oncogene bridging the RAS and NF-kappaB pathways in human lung cancer. J Clin Invest 121(10): 4095-4105.
17. Wen W, Peng C, Kim MO, Ho Jeong C, Zhu F, Yao K, Zykova T, Ma W, Carper A, Langfald A, Bode AM, Dong Z (2013) Knockdown of RNF2 induces apoptosis by regulating MDM2 and p53 stability. Oncogene; e-pub ahead of print 14 Jan 2013; doi:10.1038/onc.2012.605.
18. Wick W, Hartmann C, Engel C, Stoffels M, Felsberg J, Stockhammer F, Sabel MC, Koeppen S, Ketter R, Meyermann R, Rapp M, Meisner C, Kortmann RD, Pietsch T, Wiestler OD, Ernemann U, Bamberg M, Reifenberger G, von Deimling A, Weller M (2009) NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol 27(35): 5874-5880.